Global Oral Antidiabetic Drugs Market Growth (Status and Outlook) 2023-2029

Global Oral Antidiabetic Drugs Market Growth (Status and Outlook) 2023-2029

Diabetes mellitus is a group of a metabolic disorder caused when the body is unable to produce required quantity of Insulin. Insulin is a hormone secreted by beta cells of the islet of Langerhans of the pancreas. Various symptoms associated with diabetes disorder include recurrent urination, increased thirst, and hunger. Diabetes can cause much chronic complication if left untreated. Some of them include acute complications like diabetic ketoacidosis, chronic kidney failure, foot ulcers, and damage to the eyes.

LPI (LP Information)' newest research report, the “Oral Antidiabetic Drugs Industry Forecast” looks at past sales and reviews total world Oral Antidiabetic Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Oral Antidiabetic Drugs sales for 2023 through 2029. With Oral Antidiabetic Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Antidiabetic Drugs industry.

This Insight Report provides a comprehensive analysis of the global Oral Antidiabetic Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oral Antidiabetic Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oral Antidiabetic Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Antidiabetic Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Antidiabetic Drugs.

The global Oral Antidiabetic Drugs market size is projected to grow from US$ 1803.9 million in 2022 to US$ 2251.3 million in 2029; it is expected to grow at a CAGR of 3.2% from 2023 to 2029.

United States market for Oral Antidiabetic Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Oral Antidiabetic Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Oral Antidiabetic Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Oral Antidiabetic Drugs players cover Eli Lilly, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Merck and Pfizer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Oral Antidiabetic Drugs market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Sulfonylureas
Meglitinides
Alpha-glucosidase inhibitors

Segmentation by application
Hospitals
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Eli Lilly
Abbott
Biocon
Sanofi
Sunpharma
Novartis
Novo Nordisk
Merck
Pfizer
Huadong Medicine Co.,Ltd.
Lepu Medical
Hengrui Medicine

Please note: The report will take approximately 2 business days to prepare and deliver.